


For healthcare and medical media outside the United States and Japan

**THE BOSTON SCIENTIFIC DRUG-ELUTING STENT PROGRAMME:
*Advancing Stent Options. Now and beyond.***

Boston Scientific is the first and only company to date offer two distinct drug-eluting stent (DES) systems — the TAXUS™ Paclitaxel-Eluting Coronary Stent System and the PROMUS™ Everolimus-Eluting Coronary Stent System. PROMUS is a private-labeled XIENCE™ V Everolimus Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. The TAXUS and PROMUS Stent Systems are complementary technologies that enable Boston Scientific to serve physicians with the most advanced drug-eluting stent options available to-date. Both the TAXUS and PROMUS stents will be available on Boston Scientific's next generation Element™* Stent systems



Clinical trial results reaffirm strength of the two drug-eluting stents from Boston Scientific

The U.S. pivotal SPIRIT III clinical trial evaluated the XIENCE™ V (PROMUS) Stent compared to the TAXUS Stent. The SPIRIT III results showed that the primary endpoint of angiographic in-segment late loss at 8 months met its non-inferiority margin between the TAXUS Stent (0.28 mm) and XIENCE V/PROMUS Stent (0.14 mm), $p_{NI} < 0.0001$, $p_{superiority} = 0.004$. The TAXUS Stent results are consistent with data from previous trials in terms of low angiographic and clinical restenosis rates, with excellent safety results. The major clinical secondary endpoint of target vessel failure or TVF (a composite of death, myocardial infarction, and ischemia-driven target vessel revascularization) at 9 months also showed non-inferiority between the TAXUS Stent (9.0%) and the XIENCE V (PROMUS) Stent (7.2%), $p_{NI} < 0.0001$, $p_{superiority} = 0.31$. Although not powered as an endpoint, ischemia-driven target lesion revascularization (TLR or re-treatment rate) was comparable between the TAXUS Stent (5.0%) and the XIENCE V (PROMUS) Stent (2.6%), $p = 0.053$. TVR was also comparable between the TAXUS Stent (6.5%) and the XIENCE V (PROMUS) Stent (5.3%), $p = 0.47$.

The TAXUS Stent and XIENCE V (PROMUS) Stent demonstrated impressive safety results up to 9 months. In particular, the TAXUS Stent was associated with no stent thrombosis and no Q-wave myocardial infarction (MI or heart attack).

Clinical programmes

The TAXUS Stent has been evaluated in the TAXUS clinical trial series, including data on over 4,000 patients out to 4 years. A total of 814 diabetic patients were included in the four largest TAXUS trials (TAXUS II, IV, V and VI), which compared TAXUS stents with BMS. The results show that diabetic patients have significantly better outcomes at 9 months and again at 4 years if they are treated with a TAXUS stent. In addition, data is available on over 20,000 real-world patients in the ARRIVE, Wisdom, Milestone 2, and Olympia registries.

The XIENCE V (PROMUS) Stent has been evaluated in the SPIRIT clinical trial series, including data on over 1,600 patients.

European and US approval status

The TAXUS Liberté Stent System is approved in Europe and in 18 other international markets in South America and Asia Pacific to date. It also has received European CE Mark approval for use in patients with diabetes.² Boston Scientific completed the filing for pre-marketing approval of TAXUS Liberté with the US Food and Drug Administration (FDA) in March 2006.

The PROMUS Stent received CE Mark approval in October 2006 allowing Boston Scientific to distribute the stent in 27 countries of the European Economic Area. It will also be available in selected countries in Asia, Latin America and Eastern Europe. A US launch is planned for 2008.

The TAXUS Liberté and XIENCE V (PROMUS) Stent Systems are not available for sale in the United States.

¹ SPIRIT is sponsored by Abbott. SPIRIT III Presentation, ACC 2007; Presented by Stone GW. SPIRIT I in Serruys, et al., Eurointervention 2005, 1:58-65, SPIRIT II in Serruys, et al., Eurointervention 2006, 2 :286-294.

² For patients with concomitant diabetes mellitus.

* Element™ is under development, not available for sale in the EEA. For information purpose only.
XIENCE is a Trademark of Abbott laboratories group of companies

All cited trademarks are the property of their respective owners.

###

For further inquiries, please contact:

Geraldine Varoqui
Boston Scientific PR Manager
Tel: +49 2102 489 461
varoqui@bsci.com

OR

Tracy Paul
BSC press office
Tel: + 44 (0) 20 7413 3101
tpaul@medicalknowledgegroup.com